With the IMpower150 study, atezolizumab plus bevacizumab, carboplatin, and paclitaxel has been approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as a first-line treatment for patients with advanced non-squamous NSCLC, regardless of PD-L1 expression level (5). Here, CD274 is linked to non-small cell lung carcinoma.